scispace - formally typeset
M

Martina Fabris

Researcher at University of Udine

Publications -  122
Citations -  3641

Martina Fabris is an academic researcher from University of Udine. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 31, co-authored 96 publications receiving 2721 citations. Previous affiliations of Martina Fabris include Catholic University of the Sacred Heart.

Papers
More filters
Journal ArticleDOI

Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study

TL;DR: Encouraging results justify future randomised controlled trials of belimumab in a selected target population of pSS patients most likely to benefit from treatment.
Journal ArticleDOI

Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients.

TL;DR: The prevalence of post-coronavirus disease 2019 (COVID-19) syndrome was 40.2% (241/599) and the presence of IgG antibodies against SARS-CoV-2 was significantly associated with the occurrence of post COVID19 syndrome (OR 2.56, 95% CI 1.48-4.38, p 0.004) as mentioned in this paper.
Journal ArticleDOI

Pro inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomes.

TL;DR: It is demonstrated that the treatment with inflammatory cytokines increases the immunosuppressive and anti-inflammatory potential of AMSCs-derived exosomes, which acquire the ability to shift macrophages from M1 to M2 phenotype by shuttling miRNA regulating macrophage polarization.
Journal ArticleDOI

BLyS upregulation in Sjögren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands

TL;DR: Higher s-BLyS levels and tissue clonal B-cell expansion characterize SS with B- cell lymphoproliferative disorders, even at prelymphomatous stages, and this subgroup of SS patients showed the highest EULAR SS disease activity index scores.
Journal ArticleDOI

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.

TL;DR: Higher inflammatory markers, more infections and worse outcomes characterized ventilated TOCI cases compared to ward based TOCi, which suggests that therapy time in anti-cytokine randomized trials will be key.